___

• Aagaard, L., Kristensen, K. (2014). Access to crossborder health care services for patients with rare diseases in the European Union. Orphan Drugs: Research and Reviews, 39–45.
• Akıcı, A., Ulupınar, S. (2015). The Role of Patient Care Personnel in Rational Drug Use, Social Security Institution Brochure, http://gss.sgk.gov.tr/aik/toplum/hastayardimci/doc/hastabakimaikbrosur.pdf (accessed May 2015).
• Balık, İ. (2014). Association of Research-Based Pharmaceutical Companies (AIFD) Rare Diseases and Orphan Medicine Symposium Orphan Drug Regulation Workshop Book, 13-14 September.
• Blankart, R.C., Stargardt, T., Schreyogg, J. (2011). Availability of and access to orphan drugs. Pharmacoeconomics, 29:63–82.
• Çalışkan, Z. (2008). Referans Fiyat ve İlaç Piyasası. Hacettepe Journal of Health Administration,11(1), 50-75. Campos-Castell, J. (2001). Orphan drugs and orphan diseases (Spanish). Rev Neurol., 33, 216-220.
• Dear, J.W., Lilitkarntakul, P., Webb, D.J. (2006). Are rare diseases still orphans or happily adopted? The challenges of developing and using orphan medicinal products. Br J Clin Pharmacol, 62, 264-271
• Denis, A., Mergaert, L., Fostier, C., Cleemput, I., Simoens, S. (2010). Issues surrounding orphan disease and orphan drug policies in Europe. Appl Health Econ Health Policy., 8, 343-50.
• Developing Products for Rare Diseases & Conditions. U.S. Department of Health and Human Service, https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm (accessed 7 February 2010)
• Dionisi-Vici, C., Rizzo, C., Burlina, A.B., Caruso, U., Sabetta, G., Uziel, G., A,beni, D. (2002). Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. J Pediatr, 140(3), 321-7.
• Dündar, M., Karabulut, S.Y. (2010). Rare Disease and Orphan Drugs in Turkey; Medical and Social Problem. Erciyes Medical Journal, 32(3), 195-200.
• European Medicines Agency, https://www.ema.europa.eu/en/human-regulatory/overview/orphandesignation- overview (accessed 15 October 2016)
• Haffner, M.E., Torrent-Farnell J., Maher, P.D. (2008). Does orphan drug legislation really answer the needs of patients?, Lancet. 14, 371(9629):2041-4. doi: 10.1016/S0140-6736(08)60873-9.
• Gammie, T., Lu, C.Y., Babar, Z.D. (2015). Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries. PlosOne., 10, 1-24.
• Hadjivasiliou, A. (2014). Orphan Drug Report 2014. Evaluate Pharma., 3-19
• Kesselheim, A.S., Myers, J.A., Avorn, J. (2011). Characteristics of clinical trials to support approval of orphan vs non-orphan drugs for cancer. JAMA., 305, 2320-2326.
• Orphanet’ Rare diseases in numbers: preliminary report from an ongoing bibliographic study initiated by Eurordis in partnership with Orphanet, https://www.orpha.net/actor/Orphanews/2005/doc/Rare_ Diseases_in_Numbers.pdf (accessed 10 December 2016)
• Özbek, U. (2014). İstanbul University, Experimental Medicine Research Institute (DETAE), Orphanet-Turkey, Rare Diseases and Orphan Medicine Symposium, 13-14 September.
• Pedro, F. (2013). Orphan Drugs: the regulatory environment. Drug Discov Today., 18, 163–72.
• Sosyal Güvenlik Kurumu Çalışanlarının Akılcı İlaç Kullanımındaki Etkin Rolü ve Farmakoekonomi. (2013). Book T.C. Social Security Institution, Publication No: 114
• Stolk, P., Willemen, M.J., Leufkens, H.G. (2006). Rare essentials: drugs for rare diseases as essential medicines. Bull World Health Organ., 84, 745-751.
• Taruscio, D., Cerbo, M. (1999). Rare diseases: general principles, specific problems, and health interventions (Italian). Ann Ist Super Sanita, 35, 237-244.
• Wastfelt, M., Fadeel, B., Henter, J.I. (2006). A journey of hope: lessons learned from studies on rare diseases and orphan drugs. J Intern Med, 260, 1-10.
• Wetterauer, B., Schuster, R. (2008). Rare diseases. Funding programs in Germany and Europe (German). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz., 5, 519-528.